about
Analysis of BCLI, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas.Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.How to improve effectiveness of pegvisomant treatment in acromegalic patients.Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas.Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study.PREOPERATIVE TREATMENT WITH METYRAPONE IN PATIENTS WITH CUSHING'S SYNDROME DUE TO ADRENAL ADENOMACardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year predictionIncreased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegalyAdrenocortical Carcinoma with HypercortisolismAutonomous hypercortisolism: definition and clinical implicationsRecovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical CarcinomaMay an adrenal incidentaloma change its nature?Is Follow-up of Adrenal Incidentalomas Always Mandatory?Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management optionsMitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant TreatmentMitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical CarcinomaFirst report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapyDetermination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patientsGSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly
P50
Q36138264-04E1BA23-5E62-4BB1-90F9-A08735E3A91AQ42513305-5F1CFC89-D237-4EFD-805C-D5C2316B12B9Q53720920-1443011C-2D8B-4FDF-9525-03787060D66AQ53793757-0ED22F73-DC49-4AB3-9931-B8EB66F6A224Q53799921-7146CBFF-88FF-4378-8B35-47238262FD0FQ57822711-EF594CEC-8464-4ED0-8AC0-3CFF537BC049Q86854184-C38CE4DD-9F04-4ED9-8146-553532787794Q87279410-5CF3BEC9-05DE-4118-9283-799574395786Q88652830-A33F6FA3-FCF1-47A6-A403-6CA32B1CA356Q89378928-1795C7ED-A186-47D4-A9AF-C4B2DB9D69D6Q90270690-FC7B7760-2E49-4454-9D90-699E85A8FA45Q90374739-809BD20F-C3CE-4081-B80F-C71311C156BBQ90616769-D03BCF5A-DB8F-4C15-99D7-CADFC5FE8D66Q90998574-B24A357A-FB62-4638-A895-316B09B44D83Q91097195-9C9993EC-A4B1-4C21-AF1F-72C4FD11DA9CQ91548256-CB757114-12D8-4460-A25E-7FA1259CB93FQ91651995-381AE612-84E2-4613-8C1C-1AA7B61C0F07Q92532677-3C990B6A-68D7-409C-AE78-399D8250B48FQ93385469-1EB2CD6D-4157-4BDD-93B7-0A7D83CAD1CE
P50
description
investigador
@es
researcher
@en
name
Soraya Puglisi
@en
type
label
Soraya Puglisi
@en
prefLabel
Soraya Puglisi
@en
P31
P496
0000-0002-2883-6139